{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:27:56Z","timestamp":1777868876819,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enzyme"],"abstract":"<jats:p>Gamma-glutamyltranspeptidase (GGT) and alkaline phosphatase (ALP) were\nassayed in the sera of 27 patients affected with Graves\u2019 disease prior to conventional (12-18\nmonths) methimazole (30-5 mg\/day) treatment, who were subsequently followed up over\n36 \u00b1 1.5 months (m \u00b1 SEM). Twelve patients underwent recurrence of thyrotoxicosis (relapsers)\nat variable intervals from withdrawal of treatment, whereas the remaining 12\nremained euthyroid (nonrelapsers). In the study group as a whole, both GGT and ALP serum\nlevels were significantly (p &lt; 0.001) increased with respect to 24 sex- and age-matched\neuthyroid controls (31.8 \u00b1 3.6 vs. 11.5 \u00b1 1.2 U\/l and 203 \u00b1 13.8 vs. 110 \u00b1 7.3 U\/l, m \u00b1\nSEM). Prevalence of GGT and ALP elevations was 56% (15\/27) and 58% (15\/26), respectively.\nSerum GGT activity was age dependent (r = 0.466, p &lt; 0.05) and inversely related to log(2)\nmicrosomal antibody initial titer (r = -0.499, p &lt; 0.05) in the whole series. There was no\ndifference in mean pretreatment thyroxine (T(4)) or triiodothyronine (T(3)) between the groups\nwith supranormal enzyme and normal enzyme levels. However, in the group with enhanced\nenzyme levels, relapsed patients had higher initial T(4) (20.3 \u00b1 0.8 vs. 17.1 \u00b1 0.7 \u00b5g\/dl, p &lt;\n0.01) and lower both initial T(3) (452 \u00b1 31.1 vs. 551 \u00b1 57.8 ng\/dl, p &lt; 0.02) than the\nnonrelapsed patients. Only in this group, initial T(3):T(4) ratio was a valuable indicator of the\noutcome of the disease, since it was below 30 in 7\/7 (100%) relapsers vs. 2\/8 (25%) nonrelapsers,\nbut above 30 only in 6 subjects who remitted.<\/jats:p>","DOI":"10.1159\/000469364","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:22:28Z","timestamp":1502472148000},"page":"64-70","source":"Crossref","is-referenced-by-count":2,"title":["Gamma-Glutamyltranspeptidase and Alkaline Phosphatase Serum Activities: Their Relation to the Outcome of Graves\u2019 Disease"],"prefix":"10.1159","author":[{"given":"Salvatore","family":"Benvenga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Melluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Vermiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Enzyme"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000469364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:48:29Z","timestamp":1777553309000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000469364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000469364","archive":["Portico"],"relation":{},"ISSN":["0013-9432","2504-2564"],"issn-type":[{"value":"0013-9432","type":"print"},{"value":"2504-2564","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}